Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative)

v3.22.1
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Oct. 12, 2018
Aug. 20, 2018
Mar. 31, 2022
Mar. 31, 2021
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]        
Cash paid for acquisition   $ 10,000    
Aggregate purchase price, Shares   20,000    
Aggregate purchase price, value   $ 236,000    
Patent acquired $ 15,200      
Estimated useful lives 13 years      
Intellectual Property [Member]        
Amortization expense     $ 0 $ 13,795
Estimated useful lives     5 years  
Patents [Member]        
Amortization expense     $ 295 $ 295
Accumulated amortization     4,110  
Impairment loss     141,480  
Intellectual property, carrying value     $ 0